Printer Friendly

Stem cell-based treatment of type 2 diabetes effective in mice.

VANCOUVER, B.C., March 19, 2015 -- A combination of human stem cell transplantation and antidiabetic drugs proved to be highly effective at improving body weight and glucose metabolism in a mouse model of type 2 diabetes. The findings could set the stage for clinical trials to test the first stem cell-based approach for insulin replacement in patients with type 2 diabetes.

Type 2 diabetes, which accounts for 90 percent -95 percent of the now approaching 400 million cases of diabetes worldwide, is currently treated by oral medication, insulin injections, or both to control blood glucose levels. However, insulin delivery is imprecise, onerous, and often promotes weight gain, while drugs do not work in some patients and may cause gastrointestinal problems or low blood glucose levels, high-lighting the strong need for better treatment options.

To address this need, senior study author Timothy Kieffer of the University of British Columbia collaborated with BetaLogics, a division of Janssen Research & Development, LLC, and tested a promising stem cell transplantation approach.

First, they fed mice a high-fat diet to induce obesity, low responsiveness to insulin, and high blood glucose levels--the hallmarks of type 2 diabetes. The mice then received transplants of encapsulated pancreatic progenitor cells derived from human embryonic stem cells. These transplanted cells matured into insulin-secreting beta cells, resulting in improvements in insulin sensitivity and glucose metabolism. Moreover, stem cell transplantation combined with currently available antidiabetic drugs resulted in rapid weight loss in the mice and more significant improvements in glucose metabolism compared with either treatment alone.

Moving forward, the researchers will use their mouse model of type 2 diabetes to test the effectiveness of transplanting more mature insulin-producing cells that could potentially reverse symptoms of diabetes faster and at a lower dose compared to pancreatic progenitor cells.

A similar stem cell-based transplantation approach recently obtained clearance from the US Food and Drug Administration and Health Canada to be tested in patients with type 1 diabetes in phase 1/2 clinical trials sponsored by regenerative medicine company ViaCyte.

"Success in these clinical trials could pave the way for testing in patients with type 2 diabetes," Kieffer said.

Citation: Jennifer E. Bruin et al.; "Treating Diet-Induced Diabetes and Obesity with Human Embryonic Stem Cell-Derived Pancreatic Progenitor Cells and Antidiabetic Drugs"; Stem Cell Reports, 2015 DOI: 10.1016/j.stemcr.2015.02.011

Abstract: http://goo.gl/4JAlKL

Contact: Timothy J. Kieffer, tim.kieffer@ubc.ca

COPYRIGHT 2015 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Precilinical Research
Publication:Stem Cell Research News
Date:Mar 30, 2015
Words:400
Previous Article:Stem cells may improve healing in rotator cuff surgery.
Next Article:Key to making neurons from stem cells discovered.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters